3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 4
1
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
8
Neoplasms
3
Skin Neoplasms
1
Skin Diseases
1
Neoplasm Metastasis
1
Colorectal Cancer Metastatic
1
Interventions
Dacarbazine
4
pembrolizumab
3
binimetinib
3
Nivolumab
3
encorafenib
2
cemiplimab
2
Sirolimus
2
Ipilimumab
2
vitespin
1
trametinib
1
tilsotolimod
1
spartalizumab
1
oblimersen
1
linrodostat
1
lifileucel
1
gp100 Melanoma Antigen
1
dabrafenib
1
bempegaldesleukin
1
aldesleukin
1
Vinblastine
1
Vemurafenib
1
Tretinoin
1
Tacrolimus
1
Standard of Care
1
Sodium Chloride
1
Radiotherapy
1
Radiation
1
Interleukin-2
1
Interferon-alpha
1
Interferon alpha-2
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Skin Neoplasms
×
Vemurafenib
×
Clear all
NCT01909453
2026-02-27
COLUMBUS
Pfizer
Phase 3
Completed
921 enrolled
48 charts
1 FDA